References analysis of the Wikipedia article "Cannabis use and trauma" in the English version

doi.org

Hyman SM, Sinha R (June 2009). "Stress-related factors in cannabis use and misuse: implications for prevention and treatment". Journal of Substance Abuse Treatment. 36 (4): 400–13. doi:10.1016/j.jsat.2008.08.005. PMC 2696937. PMID 19004601.

Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ (August 2007). "Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users". Journal of Traumatic Stress. 20 (4): 577–86. doi:10.1002/jts.20243. PMID 17721963.

Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC (September 2015). "Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample". Psychology of Addictive Behaviors. 29 (3): 633–8. doi:10.1037/adb0000110. PMC 4699174. PMID 26415060.

Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". The Lancet. Psychiatry. 6 (12): 995–1010. doi:10.1016/s2215-0366(19)30401-8. PMC 6949116. PMID 31672337.

Dagan Y, Yager J (August 2020). "Cannabis and Complex Posttraumatic Stress Disorder: A Narrative Review With Considerations of Benefits and Harms". The Journal of Nervous and Mental Disease. 208 (8): 619–627. doi:10.1097/nmd.0000000000001172. PMID 32433200. S2CID 218766009.

Browne KC, Dolan M, Simpson TL, Fortney JC, Lehavot K (September 2018). "Regular past year cannabis use in women veterans and associations with sexual trauma". Addictive Behaviors. 84: 144–150. doi:10.1016/j.addbeh.2018.04.007. PMC 6716375. PMID 29684763.

Loflin M, Earleywine M, Bonn-Miller M (May 2017). "Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD". Addictive Behaviors. 68: 18–23. doi:10.1016/j.addbeh.2017.01.008. PMID 28088054.

Buckner JD, Zvolensky MJ, Schmidt NB (November 2012). "Cannabis-related impairment and social anxiety: the roles of gender and cannabis use motives". Addictive Behaviors. 37 (11): 1294–7. doi:10.1016/j.addbeh.2012.06.013. PMID 22766487.

Buckner JD, Schmidt NB (November 2008). "Marijuana effect expectancies: relations to social anxiety and marijuana use problems". Addictive Behaviors. 33 (11): 1477–1483. doi:10.1016/j.addbeh.2008.06.017. PMC 2556243. PMID 18694625.

Werner KB, McCutcheon VV, Agrawal A, Sartor CE, Nelson EC, Heath AC, Bucholz KK (May 2016). "The association of specific traumatic experiences with cannabis initiation and transition to problem use: Differences between African-American and European-American women". Drug and Alcohol Dependence. 162: 162–9. doi:10.1016/j.drugalcdep.2016.03.003. PMC 4833569. PMID 27012434.

Houston JE, Murphy J, Shevlin M, Adamson G (November 2011). "Cannabis use and psychosis: re-visiting the role of childhood trauma". Psychological Medicine. 41 (11): 2339–48. doi:10.1017/S0033291711000559. PMID 21557896. S2CID 32270892.

Walukevich-Dienst K, Dylanne Twitty T, Buckner JD (May 2019). "Sexual minority women and Cannabis use: The serial impact of PTSD symptom severity and coping motives". Addictive Behaviors. 92: 1–5. doi:10.1016/j.addbeh.2018.12.012. PMID 30553032. S2CID 56172257.

Dworkin ER, Kaysen D, Bedard-Gilligan M, Rhew IC, Lee CM (November 2017). "Daily-level associations between PTSD and cannabis use among young sexual minority women". Addictive Behaviors. 74: 118–121. doi:10.1016/j.addbeh.2017.06.007. PMC 5538382. PMID 28618391.

Gonzalez CA, Gallego JD, Bockting WO (August 2017). "Demographic Characteristics, Components of Sexuality and Gender, and Minority Stress and Their Associations to Excessive Alcohol, Cannabis, and Illicit (Noncannabis) Drug Use Among a Large Sample of Transgender People in the United States". The Journal of Primary Prevention. 38 (4): 419–445. doi:10.1007/s10935-017-0469-4. PMC 5516932. PMID 28405831.

Goldbach JT, Schrager SM, Dunlap SL, Holloway IW (February 2015). "The application of minority stress theory to marijuana use among sexual minority adolescents". Substance Use & Misuse. 50 (3): 366–75. doi:10.3109/10826084.2014.980958. PMID 25493644. S2CID 23419207.

Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P (October 2009). "Cannabis and anxiety: a critical review of the evidence". Human Psychopharmacology. 24 (7): 515–23. doi:10.1002/hup.1048. PMID 19693792. S2CID 13544234.

Braida D, Limonta V, Malabarba L, Zani A, Sala M (January 2007). "5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats". European Journal of Pharmacology. 555 (2–3): 156–63. doi:10.1016/j.ejphar.2006.10.038. PMID 17116299.

Degenhardt L, Hall W, Lynskey M (November 2003). "Exploring the association between cannabis use and depression". Addiction. 98 (11): 1493–504. doi:10.1046/j.1360-0443.2003.00437.x. PMID 14616175.

Pertwee RG (January 2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.

Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012-06-26). "Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence". Drug Testing and Analysis. 4 (7–8): 649–59. doi:10.1002/dta.1377. PMID 22736575.

Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF (December 2001). "Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission". The Journal of Neuroscience. 21 (23): 9506–18. doi:10.1523/jneurosci.21-23-09506.2001. PMC 6763903. PMID 11717385.

Walker JM, Huang SM (2002). "Cannabinoid analgesia". Pharmacology & Therapeutics. 95 (2): 127–135. doi:10.1016/S0163-7258(02)00252-8. PMID 12182960.

Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M (September 2010). "Structural MRI findings in long-term cannabis users: what do we know?". Substance Use & Misuse. 45 (11): 1787–808. doi:10.3109/10826084.2010.482443. PMID 20590400. S2CID 22127231.

Jacobson L, Sapolsky R (May 1991). "The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis". Endocrine Reviews. 12 (2): 118–34. doi:10.1210/edrv-12-2-118. PMID 2070776.

Perron RR, Tyson RL, Sutherland GR (December 2001). "Delta9 -tetrahydrocannabinol increases brain temperature and inverts circadian rhythms". NeuroReport. 12 (17): 3791–4. doi:10.1097/00001756-200112040-00038. PMID 11726796. S2CID 25466602.

Babson KA, Sottile J, Morabito D (April 2017). "Cannabis, Cannabinoids, and Sleep: a Review of the Literature". Current Psychiatry Reports. 19 (4): 23. doi:10.1007/s11920-017-0775-9. PMID 28349316. S2CID 7429763.

Vaughn S, Cirino PT, Wanzek J, Wexler J, Fletcher JM, Denton CD, et al. (2010-03-01). "Response to Intervention for Middle School Students With Reading Difficulties: Effects of a Primary and Secondary Intervention". School Psychology Review. 39 (1): 3–21. doi:10.1080/02796015.2010.12087786. PMC 3072689. PMID 21479079.

Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. (2013-01-01). "Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers". Journal of Analytical Toxicology. 37 (1): 11–6. doi:10.1093/jat/bks081. PMC 3584989. PMID 23074216.

Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA (January 2014). "Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users". The American Journal of Drug and Alcohol Abuse. 40 (1): 23–30. doi:10.3109/00952990.2013.821477. PMID 24205805. S2CID 8988512.

Metrik J, Jackson K, Bassett SS, Zvolensky MJ, Seal K, Borsari B (November 2016). "The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with PTSD and MDD". Psychology of Addictive Behaviors. 30 (7): 743–754. doi:10.1037/adb0000210. PMC 5218528. PMID 27786514.

Cameron C, Watson D, Robinson J (October 2014). "Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation". Journal of Clinical Psychopharmacology. 34 (5): 559–64. doi:10.1097/jcp.0000000000000180. PMC 4165471. PMID 24987795.

Fraser GA (2009). "The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)". CNS Neuroscience & Therapeutics. 15 (1): 84–8. doi:10.1111/j.1755-5949.2008.00071.x. PMC 6494011. PMID 19228182.

Jetly R, Heber A, Fraser G, Boisvert D (January 2015). "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study". Psychoneuroendocrinology. 51: 585–8. doi:10.1016/j.psyneuen.2014.11.002. PMID 25467221. S2CID 29692607.

Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A (August 2014). "Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder". Clinical Drug Investigation. 34 (8): 587–91. doi:10.1007/s40261-014-0212-3. PMID 24935052. S2CID 4881658.

Carlini EA, Cunha JM (1981-08-09). "Hypnotic and antiepileptic effects of cannabidiol". Journal of Clinical Pharmacology. 21 (S1): 417S – 427S. doi:10.1002/j.1552-4604.1981.tb02622.x. PMID 7028792. S2CID 7372390.

Nicholson AN, Turner C, Stone BM, Robson PJ (June 2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults". Journal of Clinical Psychopharmacology. 24 (3): 305–13. doi:10.1097/01.jcp.0000125688.05091.8f. PMID 15118485. S2CID 4846127.

Hsiao YT, Yi PL, Li CL, Chang FC (January 2012). "Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats". Neuropharmacology. Anxiety and Depression. 62 (1): 373–84. doi:10.1016/j.neuropharm.2011.08.013. PMID 21867717. S2CID 20340120.

Chagas MH, Crippa JA, Zuardi AW, Hallak JE, Machado-de-Sousa JP, Hirotsu C, et al. (March 2013). "Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats". Journal of Psychopharmacology. 27 (3): 312–6. doi:10.1177/0269881112474524. PMID 23343597. S2CID 5125324.

nih.gov

pubmed.ncbi.nlm.nih.gov

Walker JM, Huang SM (2002). "Cannabinoid analgesia". Pharmacology & Therapeutics. 95 (2): 127–135. doi:10.1016/S0163-7258(02)00252-8. PMID 12182960.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

worldcat.org

Diagnostic and statistical manual of mental disorders : DSM-5. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. (Fifth ed.). Arlington, VA. 2013. ISBN 978-0-89042-559-6. OCLC 847226928.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)

search.worldcat.org

Cannabis use and trauma (English Wikipedia)

doi.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ntu.edu.tw

ntur.lib.ntu.edu.tw

semanticscholar.org

api.semanticscholar.org

worldcat.org

worldcat.org

search.worldcat.org